Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?
Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?
With its stock down 9.4% over the past three months, it is easy to disregard Harmony Biosciences Holdings (NASDAQ:HRMY). But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to Harmony Biosciences Holdings' ROE today.
由於股票在過去三個月內下跌了9.4%,我們很容易忽視和諧生物科技控股公司(納斯達克:HRMY)。但如果你仔細觀察,你可能會發現它良好的財務狀況意味着該股票在長期內可能會看到價值增加,因爲市場通常會獎勵那些財務健康的公司。特別是,我們今天將關注和諧生物科技控股公司的ROE。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
股本回報率(ROE)是衡量公司如何有效地增長其價值和管理投資者資金的指標。簡單來說,它衡量公司的盈利能力相對於股東權益的情況。
How To Calculate Return On Equity?
如何計算股東權益回報率?
ROE can be calculated by using the formula:
ROE可以通過以下公式計算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股東權益回報率 = 凈利潤(來自持續運營)÷ 股東權益
So, based on the above formula, the ROE for Harmony Biosciences Holdings is:
根據上述公式,和諧生物科技控股公司的ROE爲:
21% = US$123m ÷ US$597m (Based on the trailing twelve months to September 2024).
21% = 12300萬美元 ÷ 59700萬美元(基於截至2024年9月的過去十二個月數據)。
The 'return' is the amount earned after tax over the last twelve months. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.21.
「回報」是指在過去十二個月內稅後所賺得的金額。因此,這意味着對於每1美元的股東投資,公司產生0.21美元的利潤。
What Has ROE Got To Do With Earnings Growth?
ROE與盈利增長有何關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
我們已經確定,ROE作爲公司未來盈利的有效盈利生成指標。根據公司選擇再投資或 "保留 "其利潤的多少,我們能夠評估公司未來產生利潤的能力。一般而言,其他條件相同,具有高股本回報率和利潤保留的公司,其增長率高於沒有這些特徵的公司。
A Side By Side comparison of Harmony Biosciences Holdings' Earnings Growth And 21% ROE
和諧生物科學控股公司盈利增長及21% ROE的並排比較
At first glance, Harmony Biosciences Holdings seems to have a decent ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 21%. This certainly adds some context to Harmony Biosciences Holdings' exceptional 66% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.
乍一看,和諧生物科學控股公司的ROE似乎不錯。與行業比較,我們發現行業平均ROE也在21%。這無疑爲和諧生物科學控股公司過去五年中66%的凈利潤增長提供了一些背景。我們認爲這裏可能還有其他因素在起作用。例如,公司的分紅派息比例較低或管理效率較高。
Next, on comparing with the industry net income growth, we found that Harmony Biosciences Holdings' growth is quite high when compared to the industry average growth of 1.2% in the same period, which is great to see.
接下來,與行業的凈利潤增長比較,我們發現在同一時期,和諧生物科學控股公司的增長遠高於行業平均增長的1.2%,這一點非常好。
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is Harmony Biosciences Holdings fairly valued compared to other companies? These 3 valuation measures might help you decide.
盈利增長是股票估值的巨大因素。投資者應嘗試確定預期的盈利增長或下降,無論是哪種情況,是否已經被定價。這將幫助他們判斷股票是處於光明還是陰暗的未來。相比其他公司,Harmony Biosciences Holdings的估值是否合理?這三個估值指標可能幫助你做出決定。
Is Harmony Biosciences Holdings Efficiently Re-investing Its Profits?
Harmony Biosciences Holdings是否有效地再投資其利潤?
Given that Harmony Biosciences Holdings doesn't pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.
鑑於Harmony Biosciences Holdings並未向其股東支付任何定期分紅,我們推測該公司一直在將其所有利潤再投資以發展其業務。
Conclusion
結論
Overall, we are quite pleased with Harmony Biosciences Holdings' performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總體來說,我們對Harmony Biosciences Holdings的表現非常滿意。具體來說,我們喜歡該公司以高回報率再投資大量利潤。這當然導致公司在盈利方面取得了顯著增長。話雖如此,最新的行業分析師預測表明,該公司的盈利增長預計將放緩。想要了解更多關於該公司未來盈利增長預測的信息,請查看這份關於該公司的分析師預測的免費報告以獲取更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。
譯文內容由第三人軟體翻譯。